In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Pluristem Therapeutics, Inc.. Trade Record

NASDAQ:PSTI Pluristem Therapeutics, Inc. stock gains 27.06% Exit Feb 4, 2019 a Trade Record by priceseries

Trade Chart
Trade Chart PSTI Jan 2, 2019, priceSeries
About Pluristem Therapeutics, Inc.

Pluristem Therapeutics Inc., through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trials, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions. The company develops placenta expanded (PLX) cell therapy products, such as PLX-PAD cells, which has been completed Phase-II clinical trial for the treatment of peripheral and cardiovascular diseases, as well as for the treatment of orthopedic diseases. It also develops PLX-R18 cells for hematopoietic cell transplantation in animals, as well as conducts various in-vivo studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Trade Information
Trade Type
LONG
ReliabilityScore™
82.46
Entry Date
Jan 2, 2019
Entry Price
8.90
Sell Date
Feb 4, 2019
Sell Price
11.31
Net Gain
27.06%
Hold Time
22 Trading Days